(Q34343254)

1 August 2017

Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment? (English)

1 reference

1 August 2017

Jun Wang

1

1 reference

PubMed ID

23649812

1 August 2017

Ming Xiang

series ordinal

2

1 reference

PubMed ID

23649812

1 August 2017

language of work or name

English

0 references

publication date

5 April 2013

1 reference

1 August 2017

1 reference

1 August 2017

33

1 reference

1 August 2017

5

1 reference

1 August 2017

515-528

1 reference

K+ channel modulators for the treatment of neurological disorders and autoimmune diseases

1 August 2017

1 reference

The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain

21 January 2018

1 reference

The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model.

21 January 2018

1 reference

Identification of a new specific Kv1.3 channel blocker, Ctri9577, from the scorpion Chaerilus tricostatus.

21 January 2018

1 reference

Cutting-edge issues in organ-specific autoimmunity.

21 January 2018

1 reference

Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases

21 January 2018

1 reference

The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy

21 January 2018

1 reference

The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression

21 January 2018

1 reference

The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis

21 January 2018

1 reference

Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences

21 January 2018

1 reference

K+ channels as targets for specific immunomodulation

21 January 2018

1 reference

Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases

21 January 2018

1 reference

Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases

21 January 2018

1 reference

Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes

21 January 2018

1 reference

Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease

21 January 2018

1 reference

Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis

21 January 2018

1 reference

Extracellular K(+) and opening of voltage-gated potassium channels activate T cell integrin function: physical and functional association between Kv1.3 channels and beta1 integrins

21 January 2018

1 reference

Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis

21 January 2018

1 reference

Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators

21 January 2018

1 reference

Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases

21 January 2018

1 reference

4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3.

21 January 2018

1 reference

Differential molecular information of maurotoxin peptide recognizing IK(Ca) and Kv1.2 channels explored by computational simulation

21 January 2018

1 reference

AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers

21 January 2018

1 reference

Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus

21 January 2018

1 reference

NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease.

21 January 2018

1 reference

Selective inhibition of CCR7(-) effector memory T cell activation by a novel peptide targeting Kv1.3 channel in a rat experimental autoimmune encephalomyelitis model

21 January 2018

1 reference

Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat.

21 January 2018

1 reference

The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation

21 January 2018

1 reference

K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity

21 January 2018

1 reference

Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection

21 January 2018

1 reference

Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block

21 January 2018

1 reference

The functional network of ion channels in T lymphocytes

21 January 2018

1 reference

Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease

21 January 2018

1 reference

Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases

21 January 2018

1 reference

Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis

21 January 2018

1 reference

Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes

21 January 2018

1 reference

The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS

21 January 2018

1 reference

Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques

21 January 2018

1 reference

Functional blockade of the voltage-gated potassium channel Kv1.3 mediates reversion of T effector to central memory lymphocytes through SMAD3/p21cip1 signaling

21 January 2018

1 reference

Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis

21 January 2018

1 reference

Kv1.3 deletion biases T cells toward an immunoregulatory phenotype and renders mice resistant to autoimmune encephalomyelitis

21 January 2018

1 reference

A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes

21 January 2018

1 reference

Potassium channel expression in human CD4+ regulatory and naïve T cells from healthy subjects and multiple sclerosis patients

21 January 2018

1 reference

Potential role of reduced basolateral potassium (IKCa3.1) channel expression in the pathogenesis of diarrhoea in ulcerative colitis.

21 January 2018

1 reference

KCNN4 gene variant is associated with ileal Crohn's Disease in the Australian and New Zealand population

21 January 2018

1 reference

Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel

21 January 2018

1 reference

A molecular trio in relapse and remission in multiple sclerosis

21 January 2018

1 reference

Therapeutic effect of all-trans-retinoic acid (at-RA) on an autoimmune nephritis experimental model: role of the VLA-4 integrin

21 January 2018

1 reference

Modulators of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels and their Therapeutic Indications

21 January 2018

1 reference

Differential Ca2+ influx, KCa channel activity, and Ca2+ clearance distinguish Th1 and Th2 lymphocytes

21 January 2018

1 reference

Blunted IgE-mediated activation of mast cells in mice lacking the Ca2+-activated K+ channel KCa3.1.

21 January 2018

1 reference

Co-cultivation of mast cells and Fc epsilon RI alpha+ dendritic-like cells from human hip bone marrow

21 January 2018

1 reference

Functional KCa3.1 K+ channels are required for human lung mast cell migration

21 January 2018

1 reference

Adenosine closes the K+ channel KCa3.1 in human lung mast cells and inhibits their migration via the adenosine A2A receptor.

21 January 2018

1 reference

Engagement of the EP2 prostanoid receptor closes the K+ channel KCa3.1 in human lung mast cells and attenuates their migration

21 January 2018

1 reference

Mast cells: emerging sentinel innate immune cells with diverse role in immunity

21 January 2018

1 reference

Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy?

21 January 2018

1 reference

Occurrence of organ-specific and systemic autoimmune diseases among the first- and second-degree relatives of Caucasian patients with connective tissue diseases: report of data obtained through direct patient interviews.

21 January 2018

1 reference

International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels

21 January 2018

1 reference

An investigation of the occurrence and properties of the mitochondrial intermediate-conductance Ca2+-activated K+ channel mtKCa3.1.

21 January 2018

1 reference

Identification and functional characterization of the intermediate-conductance Ca(2+)-activated K(+) channel (IK-1) in biliary epithelium

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1236

1 reference

1 August 2017

1 reference

PubMed ID

23649812